MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Provided By GlobeNewswire
Last update: Dec 4, 2025
SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones.
Read more at globenewswire.com
